샘플 요청 목록

 카트 문의
시장보고서
상품코드
1862283

세계의 인슐린 원료의약품(API)－시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

Insulin API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
발행일: | 리서치사: QYResearch | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

인슐린 원료의약품(API) 시장 규모는 2024년에 28억 4,900만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 4.1%로 성장하여 2031년까지 37억 6,100만 달러에 달할 것으로 예측됩니다.

본 보고서는 인슐린 원료의약품의 국경 간 산업 기반, 자본 배분 패턴, 지역 경제의 상호 의존성, 공급망 재구축, 최근 관세 조정 및 국제적인 전략적 대응 조치에 대한 종합적인 평가를 제공합니다.

인슐린 원료는 인슐린 계열 의약품 제조의 주성분으로 사용되는 생리활성 물질을 말합니다. 대장균, 효모 등 유전자 재조합 미생물을 이용한 재조합 DNA 기술로 생산됩니다. 인슐린 원제는 속효형, 중간형, 지속형 인슐린 유사체 등 다양한 인슐린 제제에 배합이 가능하며, 당뇨병 관리에 있어 매우 중요한 역할을 합니다. 2024년 세계 인슐린 원료의약품 생산량은 약 55만 8,300톤에 달하며, 세계 평균 시장 가격은 1g당 약 51달러였습니다.

인슐린은 1형 당뇨병(체내에서 인슐린을 생산하지 못해 혈당량을 조절할 수 없는 상태)을 치료하는 데 사용됩니다. 또한, 인슐린이 필요한 2형 당뇨병(인슐린을 정상적으로 이용하지 못해 혈당량을 조절할 수 없는 상태) 환자의 치료에도 사용됩니다. 현재 인슐린은 중요한 의약품으로 당뇨병 치료에 널리 활용되고 있습니다.

인슐린 원료 의약품 시장은 주로 고령화, 운동 부족, 건강에 해로운 식습관으로 인한 전 세계 당뇨병(특히 2형 당뇨병) 증가에 의해 주도되고 있습니다. 더 많은 환자들이 진단을 받으면서 인슐린 기반 치료법에 대한 수요는 특히 치료 접근성이 확대되고 있는 개발도상국에서 계속 증가하고 있습니다. 또한, 재조합 DNA 기술과 바이오시밀러 개발의 발전으로 인슐린 원료의약품의 비용 효율적인 대규모 생산이 가능해져 시장 확대와 신규 시장 진출기업 증가를 뒷받침하고 있습니다.

그러나 인슐린 원료의약품(API) 시장은 탄탄한 수요에도 불구하고 제조의 복잡성, 생물학적 제제에 대한 엄격한 규제 요건 등 심각한 문제에 직면해 있습니다. 인슐린 원료의약품의 제조는 고도의 생명공학 공정을 수반하고, 막대한 자본 투자, 숙련된 인력, 엄격한 품질관리가 필요하기 때문에 중소기업의 진입이 제한될 수 있습니다. 또한, 소수의 주요 공급업체에 의한 시장 통합과 많은 국가에서 정부의 비용 억제 정책으로 인한 가격 압력은 신규 시장 진출기업에게 장벽이 되어 제조업체의 수익률을 낮추고 있습니다.

이 보고서는 인슐린 원료의약품 세계 시장에 대해 총 판매량, 매출액, 가격, 주요 기업의 시장 점유율 및 순위를 중심으로 지역별, 국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

인슐린 원료의약품(API) 시장 규모, 추정 및 예측은 판매량(톤)과 매출액(백만 달러)으로 제시되며, 2024년을 기준 연도, 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하는 2024년부터 2031년까지의 기간으로 추정 및 예측합니다. 정량적, 정성적 분석을 통해 독자들이 인슐린 원료의약품 관련 사업 전략 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 자사 위치 분석, 정보에 입각한 사업적 판단을 내릴 수 있도록 돕습니다.

시장 세분화

기업별

  • Novo Nordisk
  • Sanofi-Aventis
  • Eli Lilly
  • Tonghua Dongbao
  • Ganlee
  • United Laboratory
  • Biocon
  • Amphastar
  • Wockhardt
  • Julphar Diabetes
  • Torrent Pharma

유형별 부문

  • 일반 인간 인슐린
  • 인슐린 아날로그

작용 시간 별 부문

  • 속효형
  • 단시간 작용형
  • 중간형
  • 장시간 작용형
  • 초장시간 작용형

용도별 부문

  • 제제 제조
  • 바이오시밀러 의약품 개발
  • 과학 연구
  • 기타

지역별

  • 북미
    • 미국
    • 캐나다
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 동남아시아
    • 인도
    • 호주
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 네덜란드
    • 북유럽 국가
    • 기타 유럽
  • 라틴아메리카
    • 멕시코
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 튀르키예
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 기타 중동 및 아프리카
LSH 25.11.25

The global market for Insulin API was estimated to be worth US$ 2849 million in 2024 and is forecast to a readjusted size of US$ 3761 million by 2031 with a CAGR of 4.1% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Insulin API cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Insulin API refers to the biologically active substance used as the primary component in the manufacturing of insulin-based medications. It is produced through recombinant DNA technology using genetically engineered microorganisms such as E. coli or yeast. The insulin API can be formulated into various insulin types, including short-acting, intermediate-acting, and long-acting insulin analogs, which are critical for the management of diabetes mellitus.In 2024, global Insulin API production reached approximately 55.83 mt, with an average global market price of around US$ 51 per g.

Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.

The insulin API market is primarily driven by the rising global prevalence of diabetes, particularly Type 2 diabetes, fueled by aging populations, sedentary lifestyles, and unhealthy diets. As more patients are diagnosed, the demand for insulin-based therapies continues to increase, especially in developing regions where access to treatment is expanding. Additionally, advancements in recombinant DNA technology and biosimilar development have enabled cost-effective and large-scale production of insulin APIs, supporting broader market growth and the entry of new players.

Despite strong demand, the insulin API market faces significant challenges, including high manufacturing complexity and stringent regulatory requirements for biologics. The production of insulin APIs involves advanced biotechnological processes, requiring substantial capital investment, skilled labor, and rigorous quality control, which can limit the participation of smaller companies. Moreover, market consolidation among a few major suppliers and pricing pressure from government cost-control policies in many countries pose hurdles for newer entrants and reduce profit margins for manufacturers.

This report aims to provide a comprehensive presentation of the global market for Insulin API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Insulin API by region & country, by Type, and by Application.

The Insulin API market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Insulin API.

Market Segmentation

By Company

  • Novo Nordisk
  • Sanofi-Aventis
  • Eli Lilly
  • Tonghua Dongbao
  • Ganlee
  • United Laboratory
  • Biocon
  • Amphastar
  • Wockhardt
  • Julphar Diabetes
  • Torrent Pharma

Segment by Type

  • Regular Human Insulin
  • Insulin Analogue

Segment by Acting

  • Rapid-acting
  • Short-acting
  • Intermediate-acting
  • Long-acting
  • Ultra-long-acting

Segment by Application

  • Preparation Production
  • Biosimilar Drug Development
  • Scientific Research
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Insulin API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Insulin API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Insulin API in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Insulin API Product Introduction
  • 1.2 Global Insulin API Market Size Forecast
    • 1.2.1 Global Insulin API Sales Value (2020-2031)
    • 1.2.2 Global Insulin API Sales Volume (2020-2031)
    • 1.2.3 Global Insulin API Sales Price (2020-2031)
  • 1.3 Insulin API Market Trends & Drivers
    • 1.3.1 Insulin API Industry Trends
    • 1.3.2 Insulin API Market Drivers & Opportunity
    • 1.3.3 Insulin API Market Challenges
    • 1.3.4 Insulin API Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Insulin API Players Revenue Ranking (2024)
  • 2.2 Global Insulin API Revenue by Company (2020-2025)
  • 2.3 Global Insulin API Players Sales Volume Ranking (2024)
  • 2.4 Global Insulin API Sales Volume by Company Players (2020-2025)
  • 2.5 Global Insulin API Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Insulin API Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Insulin API Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Insulin API
  • 2.9 Insulin API Market Competitive Analysis
    • 2.9.1 Insulin API Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Insulin API Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Insulin API as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Regular Human Insulin
    • 3.1.2 Insulin Analogue
  • 3.2 Global Insulin API Sales Value by Type
    • 3.2.1 Global Insulin API Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Insulin API Sales Value, by Type (2020-2031)
    • 3.2.3 Global Insulin API Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Insulin API Sales Volume by Type
    • 3.3.1 Global Insulin API Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Insulin API Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Insulin API Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Insulin API Average Price by Type (2020-2031)

4 Segmentation by Acting

  • 4.1 Introduction by Acting
    • 4.1.1 Rapid-acting
    • 4.1.2 Short-acting
    • 4.1.3 Intermediate-acting
    • 4.1.4 Long-acting
    • 4.1.5 Ultra-long-acting
  • 4.2 Global Insulin API Sales Value by Acting
    • 4.2.1 Global Insulin API Sales Value by Acting (2020 VS 2024 VS 2031)
    • 4.2.2 Global Insulin API Sales Value, by Acting (2020-2031)
    • 4.2.3 Global Insulin API Sales Value, by Acting (%) (2020-2031)
  • 4.3 Global Insulin API Sales Volume by Acting
    • 4.3.1 Global Insulin API Sales Volume by Acting (2020 VS 2024 VS 2031)
    • 4.3.2 Global Insulin API Sales Volume, by Acting (2020-2031)
    • 4.3.3 Global Insulin API Sales Volume, by Acting (%) (2020-2031)
  • 4.4 Global Insulin API Average Price by Acting (2020-2031)

5 Segmentation by Application

  • 5.1 Introduction by Application
    • 5.1.1 Preparation Production
    • 5.1.2 Biosimilar Drug Development
    • 5.1.3 Scientific Research
    • 5.1.4 Other
  • 5.2 Global Insulin API Sales Value by Application
    • 5.2.1 Global Insulin API Sales Value by Application (2020 VS 2024 VS 2031)
    • 5.2.2 Global Insulin API Sales Value, by Application (2020-2031)
    • 5.2.3 Global Insulin API Sales Value, by Application (%) (2020-2031)
  • 5.3 Global Insulin API Sales Volume by Application
    • 5.3.1 Global Insulin API Sales Volume by Application (2020 VS 2024 VS 2031)
    • 5.3.2 Global Insulin API Sales Volume, by Application (2020-2031)
    • 5.3.3 Global Insulin API Sales Volume, by Application (%) (2020-2031)
  • 5.4 Global Insulin API Average Price by Application (2020-2031)

6 Segmentation by Region

  • 6.1 Global Insulin API Sales Value by Region
    • 6.1.1 Global Insulin API Sales Value by Region: 2020 VS 2024 VS 2031
    • 6.1.2 Global Insulin API Sales Value by Region (2020-2025)
    • 6.1.3 Global Insulin API Sales Value by Region (2026-2031)
    • 6.1.4 Global Insulin API Sales Value by Region (%), (2020-2031)
  • 6.2 Global Insulin API Sales Volume by Region
    • 6.2.1 Global Insulin API Sales Volume by Region: 2020 VS 2024 VS 2031
    • 6.2.2 Global Insulin API Sales Volume by Region (2020-2025)
    • 6.2.3 Global Insulin API Sales Volume by Region (2026-2031)
    • 6.2.4 Global Insulin API Sales Volume by Region (%), (2020-2031)
  • 6.3 Global Insulin API Average Price by Region (2020-2031)
  • 6.4 North America
    • 6.4.1 North America Insulin API Sales Value, 2020-2031
    • 6.4.2 North America Insulin API Sales Value by Country (%), 2024 VS 2031
  • 6.5 Europe
    • 6.5.1 Europe Insulin API Sales Value, 2020-2031
    • 6.5.2 Europe Insulin API Sales Value by Country (%), 2024 VS 2031
  • 6.6 Asia Pacific
    • 6.6.1 Asia Pacific Insulin API Sales Value, 2020-2031
    • 6.6.2 Asia Pacific Insulin API Sales Value by Region (%), 2024 VS 2031
  • 6.7 South America
    • 6.7.1 South America Insulin API Sales Value, 2020-2031
    • 6.7.2 South America Insulin API Sales Value by Country (%), 2024 VS 2031
  • 6.8 Middle East & Africa
    • 6.8.1 Middle East & Africa Insulin API Sales Value, 2020-2031
    • 6.8.2 Middle East & Africa Insulin API Sales Value by Country (%), 2024 VS 2031

7 Segmentation by Key Countries/Regions

  • 7.1 Key Countries/Regions Insulin API Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 7.2 Key Countries/Regions Insulin API Sales Value and Sales Volume
    • 7.2.1 Key Countries/Regions Insulin API Sales Value, 2020-2031
    • 7.2.2 Key Countries/Regions Insulin API Sales Volume, 2020-2031
  • 7.3 United States
    • 7.3.1 United States Insulin API Sales Value, 2020-2031
    • 7.3.2 United States Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.3.3 United States Insulin API Sales Value by Application, 2024 VS 2031
  • 7.4 Europe
    • 7.4.1 Europe Insulin API Sales Value, 2020-2031
    • 7.4.2 Europe Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.4.3 Europe Insulin API Sales Value by Application, 2024 VS 2031
  • 7.5 China
    • 7.5.1 China Insulin API Sales Value, 2020-2031
    • 7.5.2 China Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.5.3 China Insulin API Sales Value by Application, 2024 VS 2031
  • 7.6 Japan
    • 7.6.1 Japan Insulin API Sales Value, 2020-2031
    • 7.6.2 Japan Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.6.3 Japan Insulin API Sales Value by Application, 2024 VS 2031
  • 7.7 South Korea
    • 7.7.1 South Korea Insulin API Sales Value, 2020-2031
    • 7.7.2 South Korea Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.7.3 South Korea Insulin API Sales Value by Application, 2024 VS 2031
  • 7.8 Southeast Asia
    • 7.8.1 Southeast Asia Insulin API Sales Value, 2020-2031
    • 7.8.2 Southeast Asia Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.8.3 Southeast Asia Insulin API Sales Value by Application, 2024 VS 2031
  • 7.9 India
    • 7.9.1 India Insulin API Sales Value, 2020-2031
    • 7.9.2 India Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.9.3 India Insulin API Sales Value by Application, 2024 VS 2031

8 Company Profiles

  • 8.1 Novo Nordisk
    • 8.1.1 Novo Nordisk Company Information
    • 8.1.2 Novo Nordisk Introduction and Business Overview
    • 8.1.3 Novo Nordisk Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.1.4 Novo Nordisk Insulin API Product Offerings
    • 8.1.5 Novo Nordisk Recent Development
  • 8.2 Sanofi-Aventis
    • 8.2.1 Sanofi-Aventis Company Information
    • 8.2.2 Sanofi-Aventis Introduction and Business Overview
    • 8.2.3 Sanofi-Aventis Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.2.4 Sanofi-Aventis Insulin API Product Offerings
    • 8.2.5 Sanofi-Aventis Recent Development
  • 8.3 Eli Lilly
    • 8.3.1 Eli Lilly Company Information
    • 8.3.2 Eli Lilly Introduction and Business Overview
    • 8.3.3 Eli Lilly Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.3.4 Eli Lilly Insulin API Product Offerings
    • 8.3.5 Eli Lilly Recent Development
  • 8.4 Tonghua Dongbao
    • 8.4.1 Tonghua Dongbao Company Information
    • 8.4.2 Tonghua Dongbao Introduction and Business Overview
    • 8.4.3 Tonghua Dongbao Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.4.4 Tonghua Dongbao Insulin API Product Offerings
    • 8.4.5 Tonghua Dongbao Recent Development
  • 8.5 Ganlee
    • 8.5.1 Ganlee Company Information
    • 8.5.2 Ganlee Introduction and Business Overview
    • 8.5.3 Ganlee Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.5.4 Ganlee Insulin API Product Offerings
    • 8.5.5 Ganlee Recent Development
  • 8.6 United Laboratory
    • 8.6.1 United Laboratory Company Information
    • 8.6.2 United Laboratory Introduction and Business Overview
    • 8.6.3 United Laboratory Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.6.4 United Laboratory Insulin API Product Offerings
    • 8.6.5 United Laboratory Recent Development
  • 8.7 Biocon
    • 8.7.1 Biocon Company Information
    • 8.7.2 Biocon Introduction and Business Overview
    • 8.7.3 Biocon Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.7.4 Biocon Insulin API Product Offerings
    • 8.7.5 Biocon Recent Development
  • 8.8 Amphastar
    • 8.8.1 Amphastar Company Information
    • 8.8.2 Amphastar Introduction and Business Overview
    • 8.8.3 Amphastar Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.8.4 Amphastar Insulin API Product Offerings
    • 8.8.5 Amphastar Recent Development
  • 8.9 Wockhardt
    • 8.9.1 Wockhardt Company Information
    • 8.9.2 Wockhardt Introduction and Business Overview
    • 8.9.3 Wockhardt Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.9.4 Wockhardt Insulin API Product Offerings
    • 8.9.5 Wockhardt Recent Development
  • 8.10 Julphar Diabetes
    • 8.10.1 Julphar Diabetes Company Information
    • 8.10.2 Julphar Diabetes Introduction and Business Overview
    • 8.10.3 Julphar Diabetes Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.10.4 Julphar Diabetes Insulin API Product Offerings
    • 8.10.5 Julphar Diabetes Recent Development
  • 8.11 Torrent Pharma
    • 8.11.1 Torrent Pharma Company Information
    • 8.11.2 Torrent Pharma Introduction and Business Overview
    • 8.11.3 Torrent Pharma Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.11.4 Torrent Pharma Insulin API Product Offerings
    • 8.11.5 Torrent Pharma Recent Development

9 Industry Chain Analysis

  • 9.1 Insulin API Industrial Chain
  • 9.2 Insulin API Upstream Analysis
    • 9.2.1 Key Raw Materials
    • 9.2.2 Raw Materials Key Suppliers
    • 9.2.3 Manufacturing Cost Structure
  • 9.3 Midstream Analysis
  • 9.4 Downstream Analysis (Customers Analysis)
  • 9.5 Sales Model and Sales Channels
    • 9.5.1 Insulin API Sales Model
    • 9.5.2 Sales Channel
    • 9.5.3 Insulin API Distributors

10 Research Findings and Conclusion

11 Appendix

  • 11.1 Research Methodology
    • 11.1.1 Methodology/Research Approach
      • 11.1.1.1 Research Programs/Design
      • 11.1.1.2 Market Size Estimation
      • 11.1.1.3 Market Breakdown and Data Triangulation
    • 11.1.2 Data Source
      • 11.1.2.1 Secondary Sources
      • 11.1.2.2 Primary Sources
  • 11.2 Author Details
  • 11.3 Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제